Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer`s Disease (AD)

Study:

A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer`s Disease

Rationale:

n/a

Purpose:

12-week, open-label study to evaluate the effectiveness and safety of donepezil hydrochloride in Hispanic patients with mild to moderate Alzheimer`s Disease (AD) in the U.S.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Alzheimer`s Disease Drug: Aricept Phase 4

Verified by Eisai Inc. March, 2011

Sponsored by: Eisai Inc.
Information provided by: Eisai Inc.
ClinicalTrials.gov identifier: NCT00230568

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Florida
Weston, Florida 33331
United States

James Prodafikas., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site